A new vaccine that has raised hopes of becoming a potent new tool in the battle against malaria seems to stop working in children after four years, according to research published Wednesday.
Mar 20, 2013
0
0
Spin and bias exist in a high proportion of published studies of the outcomes and adverse side-effects of phase III clinical trials of breast cancer treatments, according to new research published in the cancer journal Annals ...
Jan 9, 2013
0
0
(Medical Xpress)—Results of a University of Arizona Cancer Center's scientist-led clinical trial show that a drug already approved for breast and lung cancer improved progression-free survival in patients with metastatic ...
Nov 14, 2012
0
0
A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce a particular kind of brain tumor in patients with tuberous sclerosis complex (TSC)—a genetic disease ...
Nov 13, 2012
0
0
(Medical Xpress)—Acute Myeloid Leukaemia (AML) patients given a new type of 'smart drug' in addition to chemotherapy treatment are 22 per cent less likely to relapse and around 13 per cent less likely to die from their ...
Nov 12, 2012
0
0
A drug which 'reboots' a person's immune system has been shown to be an effective treatment for multiple sclerosis (MS) patients who have already failed to respond to the first drug with which they were treated (a 'first-line' ...
Oct 31, 2012
0
0
Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical ...
Sep 25, 2012
0
0
(HealthDay)—Patients with invasive malignancies who take L-carnitine supplements do not experience a reduction in fatigue, pain, or depression, according to research published online Sept. 17 in the Journal of Clinical ...
Sep 18, 2012
0
0
German pharmaceuticals maker Merck KGaA said Tuesday it is withdrawing its application for its drug Erbitux to be used to treat patients with lung cancer.
Sep 18, 2012
0
0
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the New England Journal of Medicine, show the drug extends life by an average five months in the most advanced stages of prostate cancer.
Aug 16, 2012
0
0
